Jeannine Giacovelli, a leading expert, guides you on a journey to sustainable weight loss
94 The considerations outlined in Table 4 highlight that, as newer dual- and triple-agonist therapies broaden the therapeutic landscape, individualized risk-stratification based on clinical profiles, structured monitoring, appropriate clinical management, and ongoing pharmacovigilance remain essential
Key takeaways Traveling with semaglutide requires a bit of planning since the medication needs to be stored at specific temperatures, but its very doable
This is not a telehealth prescription service
What the Clinical Evidence Says Clinical trials of GLP-1 receptor agonists have generated substantial data on this topic
In conclusion, liraglutide (Saxenda) is approved for adults with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management